Generic vs. Disease-Specific Patient Reported Outcome (PRO) Instruments for Assessing HRQoL Burden Among Patients Diagnosed with Alopecia Areata: Evidence from TARGET-DERM AA

This study evaluated the effectiveness of generic versus disease-specific patient-reported outcome instruments in assessing health-related quality of life (HRQoL) among 141 patients with alopecia areata (AA). The study found that generic QoL instruments like the SF-36 and DLQI were not sensitive enough to detect differences in HRQoL burden across different severities of AA. Significant differences were only observed in the physical component summary and physical function scores of the SF-36 for patients with varying severity, while the DLQI showed no significant differences. In contrast, the Alopecia Areata Patient Priority Outcomes (AAPPO) effectively captured significant differences in hair loss and activity limitation domains, highlighting its sensitivity to AA severity.